Other Species / Isoforms
  SFRS9 (human)      LTP 

LTP (Low Throughput Papers) : The number of records in which this modification site was determined using methods other than discovery mass spectrometry.

 HTP 

HTP (High Throughput Papers): The number of records in which this modification site was assigned using ONLY proteomic discovery mass spectrometry.

 
S2-p
______MsGWADErG
0 6
SFRS9 (human) ______MsGWADErG S2-p
SFRS9 (mouse) ______MssGWADER S2-p
SFRS9 (rat) ______MSGWADERG S2
-
gap
0 1
SFRS9 (human) gap -
SFRS9 (mouse) _____MssGWADERG S3-p
SFRS9 (rat) gap -
R8-m1
MsGWADErGGEGDGR
0 1
SFRS9 (human) MsGWADErGGEGDGR R8-m1
SFRS9 (mouse) ssGWADERGGEGDGR R9
SFRS9 (rat) MSGWADERGGEGDGR R8
Y17-p
GEGDGRIyVGNLPTD
0 6
SFRS9 (human) GEGDGRIyVGNLPTD Y17-p
SFRS9 (mouse) GEGDGRIYVGNLPSD Y18
SFRS9 (rat) GEGDGRIYVGNLPTD Y17
K28-ub
LPTDVREkDLEDLFy
Upstream
0 6
Treatment
  • MG132
SFRS9 (human) LPTDVREkDLEDLFy K28-ub
SFRS9 (mouse) LPSDVREKDLEDLFY K29
SFRS9 (rat) LPTDVREKDLEDLFY K28
Y35-p
kDLEDLFykYGRIRE
0 3
SFRS9 (human) kDLEDLFykYGRIRE Y35-p
SFRS9 (mouse) KDLEDLFYkYGRIRE Y36
SFRS9 (rat) KDLEDLFYKYGRIRE Y35
K36-ac
DLEDLFykYGRIREI
0 1
SFRS9 (human) DLEDLFykYGRIREI K36-ac
SFRS9 (mouse) DLEDLFYKYGRIREI K37
SFRS9 (rat) DLEDLFYKYGRIREI K36
K36-ub
DLEDLFykYGRIREI
Upstream
0 15
Treatment
  • MG132
SFRS9 (human) DLEDLFykYGRIREI K36-ub
SFRS9 (mouse) DLEDLFYkYGRIREI K37-ub
SFRS9 (rat) DLEDLFYKYGRIREI K36
K46-ub
RIREIELkNRHGLVP
0 2
SFRS9 (human) RIREIELkNRHGLVP K46-ub
SFRS9 (mouse) RIREIELKNRHGLVP K47
SFRS9 (rat) RIREIELKNRHGLVP K46
R63-m1
FVRFEDPrDAEDAIy
0 1
SFRS9 (human) FVRFEDPrDAEDAIy R63-m1
SFRS9 (mouse) FVRFEDPRDAEDAIy R64
SFRS9 (rat) FVRFEDPRDAEDAIY R63
Y70-p
rDAEDAIyGRNGyDY
0 129
SFRS9 (human) rDAEDAIyGRNGyDY Y70-p
SFRS9 (mouse) RDAEDAIyGRNGYDY Y71-p
SFRS9 (rat) RDAEDAIYGRNGYDY Y70
Y75-p
AIyGRNGyDYGQCRL
0 19
SFRS9 (human) AIyGRNGyDYGQCRL Y75-p
SFRS9 (mouse) AIyGRNGYDYGQCRL Y76
SFRS9 (rat) AIYGRNGYDYGQCRL Y75
R88-m1
RLRVEFPrTYGGrGG
0 9
SFRS9 (human) RLRVEFPrTYGGrGG R88-m1
SFRS9 (mouse) RLRVEFPRTYGGrGG R89
SFRS9 (rat) RLRVEFPRAYGGRGG R88
R93-m1
FPrTYGGrGGWPrGG
0 26
SFRS9 (human) FPrTYGGrGGWPrGG R93-m1
SFRS9 (mouse) FPRTYGGrGGWPrGA R94-m1
SFRS9 (rat) FPRAYGGRGGWPRAS R93
R98-m1
GGrGGWPrGGrNGPP
0 23
SFRS9 (human) GGrGGWPrGGrNGPP R98-m1
SFRS9 (mouse) GGrGGWPrGARNGPP R99-m1
SFRS9 (rat) GGRGGWPRASRNGPP R98
R101-m1
GGWPrGGrNGPPTRR
0 14
SFRS9 (human) GGWPrGGrNGPPTRR R101-m1
SFRS9 (mouse) GGWPrGARNGPPTRR R102
SFRS9 (rat) GGWPRASRNGPPTRR R101
K128-ub
SGSWQDLkDHMrEAG
0 4
SFRS9 (human) SGSWQDLkDHMrEAG K128-ub
SFRS9 (mouse) SGSWQDLKDHMREAG K129
SFRS9 (rat) SGSWQDLKDHMREAG K128
R132-m1
QDLkDHMrEAGDVCy
0 1
SFRS9 (human) QDLkDHMrEAGDVCy R132-m1
SFRS9 (mouse) QDLKDHMREAGDVCY R133
SFRS9 (rat) QDLKDHMREAGDVCY R132
Y139-p
rEAGDVCyADVQkDG
0 3
SFRS9 (human) rEAGDVCyADVQkDG Y139-p
SFRS9 (mouse) REAGDVCYADVQKDG Y140
SFRS9 (rat) REAGDVCYADVQKDG Y139
K144-ub
VCyADVQkDGVGMVE
0 4
SFRS9 (human) VCyADVQkDGVGMVE K144-ub
SFRS9 (mouse) VCYADVQKDGMGMVE K145
SFRS9 (rat) VCYADVQKDGMGMVE K144
Y152-p
DGVGMVEyLrkEDME
0 1
SFRS9 (human) DGVGMVEyLrkEDME Y152-p
SFRS9 (mouse) DGMGMVEYLRKEDME Y153
SFRS9 (rat) DGMGMVEYLRKEDME Y152
R154-m1
VGMVEyLrkEDMEyA
0 1
SFRS9 (human) VGMVEyLrkEDMEyA R154-m1
SFRS9 (mouse) MGMVEYLRKEDMEYA R155
SFRS9 (rat) MGMVEYLRKEDMEYA R154
K155-ub
GMVEyLrkEDMEyAL
0 4
SFRS9 (human) GMVEyLrkEDMEyAL K155-ub
SFRS9 (mouse) GMVEYLRKEDMEYAL K156
SFRS9 (rat) GMVEYLRKEDMEYAL K155
Y160-p
LrkEDMEyALrkLDD
0 3
SFRS9 (human) LrkEDMEyALrkLDD Y160-p
SFRS9 (mouse) LRKEDMEYALRKLDD Y161
SFRS9 (rat) LRKEDMEYALRKLDD Y160
R163-m1
EDMEyALrkLDDtkF
0 1
SFRS9 (human) EDMEyALrkLDDtkF R163-m1
SFRS9 (mouse) EDMEYALRKLDDTKF R164
SFRS9 (rat) EDMEYALRKLDDTKF R163
K164-ub
DMEyALrkLDDtkFr
0 2
SFRS9 (human) DMEyALrkLDDtkFr K164-ub
SFRS9 (mouse) DMEYALRKLDDTKFR K165
SFRS9 (rat) DMEYALRKLDDTKFR K164
T168-p
ALrkLDDtkFrSHEG
0 1
SFRS9 (human) ALrkLDDtkFrSHEG T168-p
SFRS9 (mouse) ALRKLDDTKFRSHEG T169
SFRS9 (rat) ALRKLDDTKFRSHEG T168
K169-ub
LrkLDDtkFrSHEGE
0 5
SFRS9 (human) LrkLDDtkFrSHEGE K169-ub
SFRS9 (mouse) LRKLDDTKFRSHEGE K170
SFRS9 (rat) LRKLDDTKFRSHEGE K169
R171-m1
kLDDtkFrSHEGETs
0 1
SFRS9 (human) kLDDtkFrSHEGETs R171-m1
SFRS9 (mouse) KLDDTKFRSHEGETS R172
SFRS9 (rat) KLDDTKFRSHEGETS R171
S178-p
rSHEGETsyIrVYPE
0 5
SFRS9 (human) rSHEGETsyIrVYPE S178-p
SFRS9 (mouse) RSHEGETSyIRVYPE S179
SFRS9 (rat) RSHEGETSYIRVYPE S178
Y179-p
SHEGETsyIrVYPER
0 54
SFRS9 (human) SHEGETsyIrVYPER Y179-p
SFRS9 (mouse) SHEGETSyIRVYPER Y180-p
SFRS9 (rat) SHEGETSYIRVYPER Y179
R181-m1
EGETsyIrVYPERst
0 1
SFRS9 (human) EGETsyIrVYPERst R181-m1
SFRS9 (mouse) EGETSyIRVYPERST R182
SFRS9 (rat) EGETSYIRVYPERGT R181
S187-p
IrVYPERstsyGysr
0 2
SFRS9 (human) IrVYPERstsyGysr S187-p
SFRS9 (mouse) IRVYPERSTsYGysR S188
SFRS9 (rat) IRVYPERGTSYGCSR G187
T188-p
rVYPERstsyGysrs
0 1
SFRS9 (human) rVYPERstsyGysrs T188-p
SFRS9 (mouse) RVYPERSTsYGysRs T189
SFRS9 (rat) RVYPERGTSYGCSRS T188
S189-p
VYPERstsyGysrsR
Upstream
0 55
Treatment
  • CXCL12
  • nocodazole
SFRS9 (human) VYPERstsyGysrsR S189-p
SFRS9 (mouse) VYPERSTsYGysRsR S190-p
SFRS9 (rat) VYPERGTSYGCSRSR S189
Y190-p
YPERstsyGysrsRs
0 3
SFRS9 (human) YPERstsyGysrsRs Y190-p
SFRS9 (mouse) YPERSTsYGysRsRs Y191
SFRS9 (rat) YPERGTSYGCSRSRS Y190
Y192-p
ERstsyGysrsRsGs
0 5
SFRS9 (human) ERstsyGysrsRsGs Y192-p
SFRS9 (mouse) ERSTsYGysRsRsGs Y193-p
SFRS9 (rat) ERGTSYGCSRSRSGS C192
S193-p
RstsyGysrsRsGsR
Upstream
0 24
Treatment
  • EGF
  • nocodazole
  • U0126
SFRS9 (human) RstsyGysrsRsGsR S193-p
SFRS9 (mouse) RSTsYGysRsRsGsR S194-p
SFRS9 (rat) RGTSYGCSRSRSGSR S193
R194-m1
stsyGysrsRsGsRG
0 11
SFRS9 (human) stsyGysrsRsGsRG R194-m1
SFRS9 (mouse) STsYGysRsRsGsRG R195
SFRS9 (rat) GTSYGCSRSRSGSRG R194
S195-p
tsyGysrsRsGsRGR
0 6
SFRS9 (human) tsyGysrsRsGsRGR S195-p
SFRS9 (mouse) TsYGysRsRsGsRGR S196-p
SFRS9 (rat) TSYGCSRSRSGSRGR S195
S197-p
yGysrsRsGsRGRDs
0 10
SFRS9 (human) yGysrsRsGsRGRDs S197-p
SFRS9 (mouse) YGysRsRsGsRGRDs S198-p
SFRS9 (rat) YGCSRSRSGSRGRDs S197
S199-p
ysrsRsGsRGRDsPy
0 12
SFRS9 (human) ysrsRsGsRGRDsPy S199-p
SFRS9 (mouse) ysRsRsGsRGRDsPy S200-p
SFRS9 (rat) CSRSRSGSRGRDsPY S199
S204-p
sGsRGRDsPyQsrGs
Upstream
0 195
Treatment
  • JAK_inhibitor_I
  • metastatic potential
  • nocodazole
SFRS9 (human) sGsRGRDsPyQsrGs S204-p
SFRS9 (mouse) sGsRGRDsPyQsRGs S205-p
SFRS9 (rat) SGSRGRDsPYQSRGs S204-p
Y206-p
sRGRDsPyQsrGsPH
0 3
SFRS9 (human) sRGRDsPyQsrGsPH Y206-p
SFRS9 (mouse) sRGRDsPyQsRGsPH Y207-p
SFRS9 (rat) SRGRDsPYQSRGsPH Y206
S208-p
GRDsPyQsrGsPHyF
0 13
SFRS9 (human) GRDsPyQsrGsPHyF S208-p
SFRS9 (mouse) GRDsPyQsRGsPHyF S209-p
SFRS9 (rat) GRDsPYQSRGsPHYF S208
R209-m1
RDsPyQsrGsPHyFs
0 8
SFRS9 (human) RDsPyQsrGsPHyFs R209-m1
SFRS9 (mouse) RDsPyQsRGsPHyFs R210
SFRS9 (rat) RDsPYQSRGsPHYFs R209
S211-p
sPyQsrGsPHyFsPF
Upstream
0 426
Treatment
  • EGF
  • erlotinib
  • LRRK2-IN-1
  • MG132_withdrawal
  • quinalizarin
SFRS9 (human) sPyQsrGsPHyFsPF S211-p
SFRS9 (mouse) sPyQsRGsPHyFsPF S212-p
SFRS9 (rat) sPYQSRGsPHYFsPF S211-p
Y214-p
QsrGsPHyFsPFRPy
Upstream
0 165
Treatment
  • erlotinib
SFRS9 (human) QsrGsPHyFsPFRPy Y214-p
SFRS9 (mouse) QsRGsPHyFsPFRPY Y215-p
SFRS9 (rat) QSRGsPHYFsPFRPY Y214
S216-p
rGsPHyFsPFRPy__
Upstream
1 157
Kinase, in vitro:
  • CDK2 (human)
Treatment
  • dasatinib
  • LRRK2-IN-1
  • nocodazole
  • quinalizarin
SFRS9 (human) rGsPHyFsPFRPy__ S216-p
SFRS9 (mouse) RGsPHyFsPFRPY__ S217-p
SFRS9 (rat) RGsPHYFsPFRPY__ S216-p
Y221-p
yFsPFRPy_______
0 13
SFRS9 (human) yFsPFRPy_______ Y221-p
SFRS9 (mouse) yFsPFRPY_______ Y222
SFRS9 (rat) YFsPFRPY_______ Y221